• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Axogen Inc.

    8/9/24 4:36:36 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email
    S-8 1 d831302ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 9, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    AXOGEN, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Minnesota   41-1301878

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    13631 Progress Blvd., Suite 400 Alachua, Florida   32615
    (Address of Principal Executive Offices)   (Zip Code)

    AXOGEN, INC. THIRD AMENDED AND RESTATED

    2019 LONG-TERM INCENTIVE PLAN

    PERFORMANCE BASED RESTRICTED STOCK UNIT INDUCEMENT AWARDS

    (Full title of the plan)

     

    Marc Began

    General Counsel

    Axogen, Inc.

    13631 Progress Boulevard, Suite 400

    Alachua, Florida 32615

    (386) 462-6800

     

    Jaclyn Liu, Esq.

    Morrison & Foerster LLP

    425 Market Street

    San Francisco, CA 94105

    (Name, address, telephone number, including

    area code, of agent for service)

      (Copy to)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SECURITIES

    EXPLANATORY NOTE

    Axogen, Inc. (the “Registrant”) has prepared this registration statement (this “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended, to register: (1) 2,500,000 additional shares of common stock of the Registrant (the “Common Stock”) that became available for issuance pursuant to the Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan (the “Equity Plan”) and (2) a total of up to 1,050,000 shares of Common Stock that may be issued upon the settlement of 1,050,000 performance stock units (the “Inducement PSUs”) that were granted to Michael Dale on August 9, 2024 to induce them to accept employment by the Company. The Equity Plan, including the shares of Common Stock available for issuance pursuant thereto, has been previously approved by the Registrant’s shareholders and Registration Statements of the Registrant on Form S-8 relating to the Equity Plans are effective. The Inducement PSUs were awarded outside of the Company’s stock incentive plans. The Inducement PSUs were approved by the Company’s Compensation Committee in compliance with, and in reliance on, Nasdaq Listing Rule 5635(c)(4), which exempts employee inducement grants from the general requirements of the Nasdaq Listing Rules that equity-based compensation plans and arrangements be approved by the stockholders.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8

    Pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of (i) the registration statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on August 22, 2019 (Registration No. 333-233416), (ii) the registration statement on Form S-8 filed by the Registrant with the Commission on May 11, 2021 (Registration No. 333-255992), and (iii)  the registration statement on Form S-8 filed by the Registrant with the Commission on May 31, 2022 (Registration No. 333-265321) (collectively, the “Prior Registration Statements”). Pursuant to the Prior Registration Statements, the Registrant previously registered an aggregate of 8,000,000 shares of Common Stock under the Equity Plan.

    PART II

    INFORMATION REQUIRED IN THE

    REGISTRATION STATEMENT

    Item 3. Incorporation of Certain Documents by Reference

    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

    a) The Company’s Annual Report on Form 10-K for its fiscal year ended December  31, 2023, filed with the Commission on March 5, 2024 (Commission File No. 001-36046);

    b) The Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March  31, 2024 and June 30, 2024;

    c) The Company’s Current Reports on Form 8-K, filed with the Commission on  January 4, 2024  (Item 5.02 only), March  8, 2024, May  2, 2024 (Item 2.02 only), June  7, 2024, and August 9, 2024 and the Company’s Current Reports on Form 8-K/A, filed with the Commission on January 5, 2024 and June 10, 2024; and

    d) The description of the Company’s Common Stock set forth in the Registration Statement on Form 8A12B filed with the Commission on August  6, 2013 pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.


    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.


    Item 8. Exhibits

     

    EXHIBIT

    NUMBER

      

    DESCRIPTION

      5.1    Opinion of Blue Chip Law †
     10.1*    Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August  9, 2024, by and between the Company and Michael Dale (TSR) (incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K filed on August 9, 2024).
     10.2*    Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August  9, 2024, by and between the Company and Michael Dale (Performance) (incorporated by reference to Exhibit 10.3 to the Company’s current report on Form 8-K filed on August 9, 2024).
     23.1    Consent of Blue Chip Law (contained in Exhibit 5.1). †
     23.2    Consent of Deloitte & Touche LLP, the Registrant’s Independent Registered Public Accounting Firm (filed herewith). †
     24.1    Power of Attorney (included on signature page to this Registration Statement).
     99.1    Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference from Appendix A of the Registrant’s Proxy Statement on DEF14A dated April 24, 2024 (No. 001-36046)).
    107    Filing Fee Table. †

     

    †

    Filed herewith.

    *

    Management contract or compensatory plan or arrangement.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Alachua, State of Florida, on August 9, 2024.

     

    Axogen, Inc.
    By:  

    /s/ Michael Dale

      Name: Michael Dale
      Title: Chief Executive Officer, President, and Director

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Michael Dale, Nir Naor, and Marc Began, his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this Registration Statement on Form S-8 (including, without limitation, any additional registration statement filed pursuant to Rule 462 under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


    Signature

      

    Title

     

    Date

    /s/ Michael Dale

      

    Chief Executive Officer, President, and Director

    (Principal Executive Officer)

      August 9, 2024
    Michael Dale

    /s/ Nir Naor

      

    Chief Financial Officer (Principal

    Financial Officer and Principal Accounting Officer)

      August 9, 2024
    Nir Naor

    /s/ Amy Wendell

       Director   August 9, 2024
    Amy Wendell     

    /s/ William Burke

       Director   August 9, 2024
    William Burke     

    /s/ John H. Johnson

       Director   August 9, 2024
    John H. Johnson     

    /s/ Alan M. Levine

       Director   August 9, 2024
    Alan M. Levine     

    /s/ Guido J. Neels

       Director   August 9, 2024
    Guido J. Neels     

    /s/ Paul Thomas

       Director and Chairman of the Board   August 9, 2024
    Paul Thomas     

    /s/ Dr. Joseph Tyndall

       Director   August 9, 2024
    Dr. Joseph Tyndall     

    /s/ Kathy Weiler

       Director   August 9, 2024
    Kathy Weiler     
    Get the next $AXGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    12/1/2025$40.00Outperform
    Mizuho
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on AxoGen with a new price target

    Mizuho initiated coverage of AxoGen with a rating of Outperform and set a new price target of $40.00

    12/1/25 8:24:55 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lake Street initiated coverage on AxoGen with a new price target

    Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

    3/17/25 8:23:19 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Raymond James initiated coverage on AxoGen with a new price target

    Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00

    7/1/24 7:31:31 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    SEC Filings

    View All

    Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Axogen, Inc. (0000805928) (Filer)

    1/23/26 7:01:23 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Axogen Inc.

    424B5 - Axogen, Inc. (0000805928) (Filer)

    1/23/26 7:00:59 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Axogen Inc.

    424B5 - Axogen, Inc. (0000805928) (Filer)

    1/21/26 4:59:18 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

    ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $31.00 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and com

    1/21/26 11:18:42 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Proposed Public Offering of Common Stock

    ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common stock. All of the shares to be sold in the proposed offering are to be sold by Axogen. There can be no assurance as to whether or when the offering may be comple

    1/21/26 4:09:10 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

    ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio.Full-year 2025 revenue is expected to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2

    1/12/26 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wendell Amy Mcbride sold $1,280,465 worth of shares (43,684 units at $29.31) and exercised 43,684 shares at a strike of $6.91 (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:25:23 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Weiler Kathy Johnson exercised 40,073 shares at a strike of $6.99 and sold $1,378,476 worth of shares (46,653 units at $29.55), closing all direct ownership in the company (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:25:04 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Hartley Lindsey Marie exercised 14,812 shares at a strike of $8.27 and sold $442,294 worth of shares (14,812 units at $29.86) (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:24:49 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Financials

    Live finance-specific insights

    View All

    Axogen, Inc. Reports Third Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.Net income for the quarter was $0.7 million,

    10/29/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

    ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, archived replay, and presentation slides of t

    10/15/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. Reports Second Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024, and a 16.7% increase over the first quarter of 2025.For the second quarter of 2025, gross margin was 74.2%, up from 73.8% for the second quarter of 2024, and up from 71.9% in the first quarter of 2025.Net income for the quarter was $0.6

    8/5/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    11/14/24 3:31:14 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Axogen Inc.

    SC 13G - Axogen, Inc. (0000805928) (Subject)

    11/7/24 4:34:48 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    9/10/24 4:00:03 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    View All

    Axogen Announces Chief Financial Officer Transition

    ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

    5/8/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

    3/24/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

    2/3/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care